Rosenberg Lynn, Zhang Yuqing, Coogan Patricia F, Strom Brian L, Palmer Julie R
Slone Epidemiology Center at Boston University, 1010 Commonwealth Avenue, Boston, MA 02215, USA.
Am J Epidemiol. 2009 Feb 15;169(4):473-9. doi: 10.1093/aje/kwn360. Epub 2008 Dec 13.
Oral contraceptive (OC) use has been linked to increased risk of breast cancer, largely on the basis of studies conducted before 1990. In the Case-Control Surveillance Study, a US hospital-based case-control study of medication use and cancer, the authors assessed the relation of OC use to breast cancer risk among 907 case women with incident invasive breast cancer (731 white, 176 black) and 1,711 controls (1,152 white, 559 black) interviewed from 1993 to 2007. They evaluated whether the association differed by ethnicity or tumor hormone receptor status. After control for breast cancer risk factors, the multivariable odds ratio for 1 year or more of OC use, relative to less than 1 year of use, was 1.5 (95% confidence interval: 1.2, 1.8). The estimates were similar within age strata (<50 years and >or= 50 years). The odds ratios were larger for use within the previous 10 years, long-duration use, and black ethnicity, but these differences were not statistically significant. The association of OC use with breast cancer risk did not differ according to the estrogen or progestogen receptor status of the tumor. These results suggest that OC use is associated with an increased risk of breast cancer diagnosed in recent years.
口服避孕药（OC）的使用与乳腺癌风险增加有关，这主要基于1990年以前进行的研究。在病例对照监测研究中，一项基于美国医院的药物使用与癌症病例对照研究，作者评估了1993年至2007年期间接受访谈的907例浸润性乳腺癌病例女性（731例白人，176例黑人）和1711例对照（1152例白人，559例黑人）中OC使用与乳腺癌风险的关系。他们评估了这种关联是否因种族或肿瘤激素受体状态而异。在控制了乳腺癌风险因素后，使用OC 1年或更长时间相对于使用少于1年的多变量优势比为1.5（95%置信区间：1.2，1.8）。年龄分层（<50岁和≥50岁）内的估计值相似。前10年内使用、长期使用和黑人种族的优势比更大，但这些差异无统计学意义。OC使用与乳腺癌风险的关联不因肿瘤的雌激素或孕激素受体状态而异。这些结果表明，OC使用与近年来诊断出的乳腺癌风险增加有关。
